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Abstract
Background: Liver fibrosis and its end-stage disease, cirrhosis, are major risk factors for hepatocellular carcinoma (HCC)
and present in 80 to 90 % of patients with HCC. Current genetically engineered mouse models for HCC, however,
generally do not feature liver fibrosis, which is a critical discrepancy between human HCC and murine models
thereof. In this study, we developed a simple transgenic mouse model of HCC within the context of a fibrotic liver.
Methods: Employing hydrodynamic transfection (HT), coupled with the Sleeping Beauty (SB) transposon system, liver
was stably transfected with transposons expressing cMyc and a short hairpin RNA down-regulating p53 (shp53). A chronic
liver injury model, induced by hepatotoxic carbon tetrachloride (CCl4), was applied to the transgenic mice, allowing cells
expressing cMyc plus shp53 to become malignant in the background of liver fibrosis.
Results: Livers harvested about 3 months after HT had excessive collagen deposition and activated hepatic stellate cells
surrounding the tumors. Hepatocarcinogenesis was significantly accelerated in the fibrotic livers compared to those of the
control, significantly decreasing the life span of the mice. The tumor incidence and average number of tumors
per mouse were significantly higher in the group treated with CCl4 compared to the vehicle-treated control mice,
following HT (p < 0.01).
Conclusions: Considering the simplicity and efficiency in generating HCC for fibrotic livers, the transgenic HCC
model has the potential to be effectively used in preclinical testing of HCC anticancer therapy and in studies of
hepatocarcinogenesis in fibrotic livers.
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Background
Hepatocellular carcinoma (HCC) is one of the most
prevalent and lethal cancers worldwide, ranking third
among all cancer-related mortalities and accounting for
500,000 deaths annually [1, 2]. Most patients with HCC
have a long history of chronic liver disease caused by
diverse factors including hepatitis B and C viral infec-
tion, alcohol abuse, diabetes, and obesity [3–6]. Persist-
ent injury to the liver from such factors leads to fibrotic
scars in the tissue, characterized by an excessive accu-
mulation of collagen fibers in the space of Disse [7, 8].
Liver fibrosis and its end-stage disease, cirrhosis, are
highly associated with HCC. Fibrosis and cirrhosis are
present in 80 to 90 % of patients with hepatocellular car-
cinoma and the 5-year cumulative risk for the develop-
ment of HCC in patients with cirrhosis is between 5 and
30 % [2, 9].
Genetically engineered mouse (GEM) models for HCC
have been generated for activated oncogenic signaling
pathways or inactivated tumor-suppressing pathways,
making significant contributions to our understanding of
the genetic mechanism underlying the pathogenesis
[10, 11]. Development of a GEM model usually involves
expensive and time-consuming processes, such as genetic
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manipulation of target cells, subsequent implantation, and
breeding of the animal. Furthermore, current GEM
models for HCC generally do not feature liver fibrosis,
calling into question whether the models can reliably
recapitulate human HCC [10, 12]. Given the high associ-
ation of chronic liver injury and fibrosis with the develop-
ment of human HCC, a novel animal model is needed in
which HCC is induced within the microenvironment of
hepatic injury and fibrosis.
A very elegant and simple method was recently developed
for liver-specific transgenesis in which the hydrodynamics-
based transfection (HT) method was coupled with the
Sleeping Beauty (SB) transposase system [13]. This simple
liver-specific transgenic approach allowed generation of
various HCC transgenic models with reduced time and
resources [14]. In this study we developed a transgenic
model for HCC via HT of transposons expressing cMyc
and short hairpin RNA down-regulating p53 (shp53). To
induce HCC within the context of hepatic injury and
fibrosis, mice transfected with cMyc plus shp53 were
repeatedly treated with carbon tetrachloride (CCl4), a
hepatotoxic chemical that induces chronic liver damage
[15, 16]. Using the mouse model, the effect of CCl4 treat-
ment and liver fibrosis on hepatocarcinogenesis was
investigated.
Methods
Animals
All experiments involving live mice were performed
according to the Guidelines and Regulations for the Care
and Use of Laboratory Animals in AAALAC-accredited
facilities, and were approved by the Animal Policy and
Welfare Committee of the Yonsei University College of
Medicine (Permit number: 2014–0261). The mice were
5–to 6-week-old C57BL/6 males purchased from the
Orientbio (Seongnam, Korea).
Plasmids and hydrodynamic transfection
The plasmid pT2/GFP harboring a transposon encod-
ing the enhanced green fluorescent protein (GFP) was
described previously [17]. The cDNA encoding murine
cMyc was PCR amplified from pCX-cMyc, a gift from
Dr. Shinya Yamanaka (Addgene plasmid # 19772). The
amplified cDNA replaced the GFP cDNA in pT2/GFP,
generating pT2/cMyc. The pPGK-SB13 plasmid, encoding
SB transposase under the control of the phosphoglycerate
kinase (PGK) promoter, was a gift from Dr. John Ohlfest.
The transposon plasmid, pT2/shp53/GFP4, which encodes
a short hairpin RNA against the tumor suppressor p53,
with GFP as a reporter, was a gift from Dr. John Ohlfest
and is referred to as pT2/shp53 [18]. For hydrodynamic
injection, 14 μg of pT2/cMyc and 14 μg of pT2/shp53
(or pT2/GFP as a control) were mixed with 9 μg of
pPGK-SB13 and then suspended in 2 ml of Lactated
Ringer solution. The DNA solution was injected into
the lateral tail veins of 6-week-old mice (0.1 ml/g body
weight) in less than 7 s.
Carbon tetrachloride (CCl4) treatment
CCl4 was administered to mice twice weekly at a dose of
1 ml/kg body weight [16]. Mice were monitored regu-
larly following administration of the CCl4, and treated
and sacrificed according to institutional guidelines.
Liver harvest and tissue processing
Mice were deeply anesthetized by intraperitoneal injec-
tion of zoletil (30 mg/kg) and xylazine (10 mg/kg). Livers
were harvested after a midline laparotomy incision and
then carefully inspected for tumor nodules. Extracted
livers were then immersed in 10 % neutral-buffered for-
malin. Fixed liver specimens were embedded in paraffin
blocks.
H&E staining and histopathological examination
Liver specimens embedded in paraffin blocks were
sectioned into 4-μm slices, which were stained with
hematoxylin and eosin (H&E) and picro-sirius red fol-
lowing standard protocols. Liver lesions were assessed as
described by Frith et al. [19]. Slides were analyzed and
photographed using a microscope (Eclipse Ti; Nikon,
Tokyo, Japan) equipped with a digital camera.
Western blotting
Liver tissues were homogenized and digested in 1× RIPA
buffer containing phosphatase inhibitor cocktail solution
(GenDEPOT, Barker, TX, USA). Western blot experi-
ments were performed following the standard protocol.
The following primary antibodies were used: anti-c-Myc
(ab32072; Abcam, Cambridge, UK), anti-p53 (sc-6243;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
anti-GAPDH (#2118; Cell Signaling Technology, Danvers,
MA, USA). Anti-rabbit IgG–HRP (Sigma-Aldrich, St.
Louis, MO, USA) was used as the secondary antibody.
Bands were detected using the enhanced chemilumines-
cence (ECL) Western blot detection system (Amersham
Pharmacia Biotech, Piscataway, NJ, USA).
Immunohistochemistry
Paraffin sections were deparaffinized in xylene and
rehydrated through a gradual decrease in concentration
of ethanol. The antigen epitopes were then unmasked
using sodium citrate buffer (pH 6.0). Subsequently, the
sections were incubated overnight at 4 °C with the fol-
lowing primary antibodies: anti-α-smooth muscle actin
(ab5694; Abcam), anti-c-Myc (ab32072; Abcam) and
anti-GFP (#2555; Cell Signaling Technology). After pri-
mary incubation, sections were incubated with the ap-
propriate biotinylated secondary antibodies, followed by
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treatment with freshly prepared DAB substrates
(Vector Laboratories, Burlingame, CA, USA). Sec-
tions were lightly counter-stained with hematoxylin
and mounted.
Mouse survival and statistical analysis
Mice were monitored daily for illness symptoms.
Kaplan–Meier survival data were analyzed using a log-
rank test. Statistical analyses were conducted using an
unpaired parametric Student’s t-test or Fisher’s exact
test, as appropriate. A value of p < 0.01 was taken to in-
dicate statistical significance.
Results
Mice expressing cMyc plus shp53 develop well-
differentiated HCC
Transgenic mice were developed expressing cMyc and
short hairpin RNA down-regulating p53 (shp53) in the
liver via hydrodynamics-based transfection. Inactivation
of P53 has been frequently observed across the diversity
of etiologic factors in human HCC [20, 21]. In particular,
allelic deletions or mutations in P53 have been fre-
quently detected in hepatocellular carcinoma after HBV
or HCV infection [22]. The Myc protein is a transcrip-
tion factor that promotes cell proliferation and growth,
and is overexpressed in up to 70 % of viral and alcohol-
related HCC [23–25]. Thus, overexpression of cMyc and
downregulation of p53 in the model are genetic charac-
teristics relevant to human hepatocarcinogenesis.
Transposons encoding cMyc plus shp53 (or GFP, as a
control) were mixed with plasmids expressing the SB
transposase and then hydrodynamically delivered to the
liver (Fig. 1a). Livers were harvested at 7 months post-
hydrodynamic injection (PHI). About 43.5 % (10 of 23)
of the mice developed liver tumors in the cMyc plus
shp53 group, while no mice in the cMyc plus GFP group
(n = 10) had hyperplastic nodules in their livers (Fig. 1b).
Liver tumors of cMyc plus shp53 mice showed overexpres-
sion of cMyc and down-regulation of p53, indicating that
they originated from cells transfected with the oncogene-
encoding transposons (Fig. 1c). Overexpression of cMyc
and shp53 in tumors was confirmed via IHC staining for
cMyc and GFP, respectively (Fig. 1d). IHC staining in liver
sections from the cMyc plus GFP mice revealed scattered
GFP-positive and cMyc-positive clusters consisting of 1–3
hepatocytes (Fig. 1d), suggesting that overexpression of
cMyc alone was insufficient to induce tumor in the liver.
Consistent with previous reports, no nodules were found
in livers of the 10 control mice expressing shp53 alone,
when analyzed at 7 months PHI (data not shown) [17].
Thus, the data indicate that oncogenic collaboration
between cMyc overexpression and p53 down-regulation
is required to induce tumors in the liver. Histopatho-
logical examination revealed that the tumors from the
cMyc plus shp53 group exhibited typical features of
highly differentiated hepatocellular carcinomas, with
broadened trabeculae (Fig. 1b).
Combining the transgenic HCC model with a chronic liver
injury model
To develop HCC in the background of liver fibrosis, we
attempted to induce fibrosis in livers expressing cMyc
plus shp53 via treatment with carbon tetrachloride
(CCl4), a hepatotoxic chemical that induces chronic liver
damage [15, 16]. Mice were hydrodynamically injected
with transposons encoding cMyc plus shp53, and assigned
randomly to the CCl4 and vehicle-treated groups (n = 10
for each group). Treatment was started at 15 d PHI and
performed twice per week throughout the experiment
(Fig. 2a). Cells transfected with cMyc and shp53 remained
as single cells at 15 d PHI and no lesions were observed in
the livers (Additional file 1). As a control (referred to as
‘CT’), 10 mice were treated with CCl4 without hydro-
dynamic injection.
A few mice treated with CCl4 were severely ill and
died within 1 month of treatment. A similar frequency
of lethality followed treatment with CCl4, regardless of
hydrodynamic injection (40 % for mice without hydro-
dynamic injection vs. 30 % for mice with hydrodynamic
injection), indicating that hydrodynamic injection does
not affect lethality. The mice treated with the vehicle
following hydrodynamic injection did not die. No tu-
mors were detected in the livers of mice that died during
this period. None of the mice that survived the first 30 d
of CCl4 treatment died during the remainder of the
study period.
A few mice hydrodynamically transfected with cMyc
plus shp53, and treated with CCl4 (referred to as “MPC
mice”) showed signs of discomfort starting at about 14
weeks after hydrodynamic injection. Livers were har-
vested from mice of all groups at 102 d PHI, after 87 d
of treatment (Fig. 2a). Gross examination revealed that
the CT mice (n = 6) had no hyperplastic nodules in the
liver, although the surface was somewhat rough (Fig. 2b).
Two of the ten mice transfected with cMyc plus shp53,
and then treated with the vehicle (referred to as “MP
mice”), had a single liver tumor. All remaining MPC
mice (n = 7) had multiple large tumors in the liver
(Fig. 2b). Of note, livers of MPC mice had a roughened
appearance as seen in those of CT mice.
Successful generation of a transgenic mouse model of
HCC with concurrent hepatic fibrosis
Histopathological examination revealed that liver tumors
from both MP and MPC had similarly well-differentiated
HCCs (Fig. 2c) [19]. No microscopic nodules were ob-
served in livers from the CT mice, while an increased
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number of inflammatory cells were observed in the tissue,
likely due to liver injury induced by CCl4 (Fig. 2c).
Picro-sirius red staining revealed that fibrosis was
present throughout the tissues of CT mice (Fig. 2c).
Fibrosis was not observed in tumor-bearing livers of MP
mice (Fig. 2c). In stark contrast to MP mice, MPC mice
had fibrosis in non-tumorous liver parenchyma tissue
surrounding the tumors (Fig. 2c). Liver tumors in both
A
B C
D
Fig. 1 Expression of cMyc plus shp53 in the liver induces well-differentiated HCC. a Schematic illustration of the experimental procedure to generate
transgenic livers expressing cMyc plus GFP (control), and cMyc plus shp53. Hydrodynamic transfection was performed using a mixture of indicated
plasmids. b Gross morphology (upper panels) of livers harvested from mice of each group at 7 months post hydrodynamic injection. Images of H&E
staining in liver sections are shown below. Well-differentiated HCCs developed in cMyc plus shp53 mice, while the control mice did not develop tumors.
Scale bar, 100 μm. c Protein expression levels of cMyc and p53 in liver of cMyc plus GFP mice (control) and liver tumor of cMyc plus shp53
mice. d Images of IHC staining for GFP and cMyc in liver sections of indicated groups. “T” denotes tumor and “N” denotes non-tumorous liver
parenchyma tissue. Scale bar, 100 μm
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MP and MPC mice were GFP and cMyc-positive, indi-
cating that the tumors were induced by transfection with
the oncogene-encoding transposons (Fig. 3).
Activation of hepatic stellate cells (HSCs) represents a
critical event in fibrosis, mediating secretion of fibrillar
collagens and accumulation of the extracellular matrix
components [7, 8]. In fibrotic areas around tumors in
MPC mice, activated hepatic stellate cells were observed
based on immunohistochemistry (IHC) analysis with anti-
bodies against α-SMA, a marker of activated HSC (Fig. 3)
[26]. Thus, treatment with CCl4 resulted in successful
production of a transgenic mouse model for HCC, accom-
panied by liver fibrosis within less than 4 months at a
100 % incidence.
A
B
C
Fig. 2 Application of a chronic liver injury model to the cMyc plus shp53 mice induces HCC in a fibrotic liver background. a Diagram of experimental
procedures. Starting at 15 d post hydrodynamic transfection, mice were treated with CCl4 or the vehicle twice per week for about 12 weeks. b Gross
images of representative livers of CT, MP, and MPC mice that were harvested at 102 d post hydrodynamic transfection. c H&E (200× and 40×) and
picro-sirius red staining in liver sections of indicated groups. Tumors from both MP and MPC show similar well-differentiated HCC phenotypes (upper
panels). Low-magnification images of the tumor seen in upper panels reveal boundaries between tumor (T) areas and areas of non-tumorous (N) liver
parenchyma tissue (middle panels). Images of picro-sirius red staining from the same area seen in middle panels are presented in lower panels. Note
the presence of accumulated collagen bands in the area surrounding the liver tumor in an MPC mouse. Scale bars, 200 μm for upper panels and
1 mm for middle and lower panels
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Survival of MP and MPC mice
To perform a statistical comparison of the survival of
MP and MPC mice, we replicated the experiment using
an increased number of mice. MP mice (n = 21) and
MPC mice (n = 31) were monitored for survival follow-
ing HT. As control groups, mice hydrodynamically
transfected with transposons encoding cMyc and GFP
were used (Additional file 2). As in the previous experi-
ment, treatment with CCl4 or the vehicle was started at
15 d PHI and administered twice per week thereafter.
About 23 % of the mice died within the first 30 d of
CCl4 treatment in the MPC group (i.e., within 45 days
post PHI), as observed in the previous experiment.
Again, no tumors were observed in livers of MPC mice
that died during the early period. The remaining MPC
mice (n = 24) showed signs of discomfort, starting
around 90 d PHI, and they died between 97 and 125 d
PHI. None of the MP mice died or developed illness
during this period. The treatment part of the experiment
was terminated at 150 d PHI and livers from all MP
mice (n = 21) were harvested. The Kaplan-Meier survival
analysis showed a significantly shorter life span of MPC
mice compared to the MP mice (Fig. 4a). Even when
mice that had died before 50 d PHI were excluded from
the MPC group due to CCl4-induced toxicity, a signifi-
cant difference was observed in survival of the MPC and
MP groups (p < 10−4; Fig. 4b). Therefore, treatment with
fibrosis-inducing CCl4 significantly shortened the life
span of mice expressing cMyc plus shp53. As observed
in MPC mice, control mice expressing cMyc and GFP
treated with CCl4 displayed a similar percentage of
lethality (~30 %) within the first 30 d of the treatment,
however no death was observed in the group later on
until the experiment end point (Additional file 2). Mice
Fig. 3 Images of IHC staining for cMyc, GFP and α-SMA in tumor sections. Tumors from both MP and MPC mice were stained positive for cMyc
and GFP. Note that cMyc was localized in the nuclei of tumor cells. The area surrounding tumor of MPC mice shows the presence of activated
hepatic stellate cells, based on α-SMA staining. “T” denotes tumor and “N” denotes non-tumorous liver parenchyma tissue. Scale bar, 200 μm
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that were transfected with cMyc and GFP followed by
the vehicle treatment showed no deaths throughout the
experiment. The control mice expressing cMyc and GFP
exhibited no tumors in their livers regardless of the
treatment with CCl4 when livers were investigated at
150 d PHI (data not shown).
Short life span of MPC mice is correlated with effects of
liver tumors
To determine if the short life span of MPC mice was due
to the liver tumors in the mice, livers were harvested from
MPC mice following death. All of the 24 MPC mice that
died between 97 and 125 d PHI had multiple large tumors
in their livers (Fig. 4c). Livers were harvested from MP
mice (n = 21) at 150 d PHI (the experiment end point) and
inspected for the presence of tumors. Only 38 % of the MP
mice (8 of 21 mice) had one or two small nodules in their
livers (Fig. 4c). The incidence of HCC in MPC mice was
significantly higher than in MP mice (p < 10−4; Table 1).
Inclusion of seven MPC mice that died initially due to
CCl4-induced toxicity reduced the incidence to 77 % in
that group (24 of 31 mice), but the incidence was still sig-
nificantly higher compared to that for MP mice (p < 0.01).
The average tumor number of MPC group livers was
about 15-fold that in the MP group (p < 10−4; Table 1).
The difference was larger when the seven MPC mice
that died early in the study were excluded, as they did
not have tumors.
The increased number of tumor nodules observed in
MPC mice suggests that the fibrotic environment induced
by CCl4 treatment enhanced tumor initiation induced by
cMyc overexpression and p53 down-regulation. Further-
more, the liver tumors in the MPC group appeared larger
than those in the MP group (Fig. 4c), suggesting that the
growth of tumors induced by cMyc plus shp53 was
accelerated in fibrotic livers. Overall, the increased
tumor burden in the liver of MPC mice likely led to a
shortened life span.
A B
C
Fig. 4 Short life span of MPC mice and increased tumor burdens in their livers. a, b Kaplan–Meier survival curves of MP and MPC mice in the entire
cohort (a) and with the exclusion of mice that died initially due to CCl4-induced toxicity (b). Note that MPC mice had a significantly shorter life span
compared to MP mice, even with the exclusion of the mice that died early in the MPC group (p < 0.0001). c Gross images of representative livers of
MP and MPC mice. Livers were harvested following death for the MPC group and at the end of the experiment in the MP group
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Discussion
In the present study, we developed a transgenic model
system in which HCC was induced by oncogenic expres-
sion in the background of liver fibrosis, mimicking hu-
man hepatocarcinogenesis. Treatment with CCl4 not
only induced liver fibrosis in non-tumorous parenchyma
surrounding HCC but also accelerated the carcinogenic
process induced by cMyc plus shp53 in the model, de-
veloping HCC within 3 months of treatment. Treatment
with CCl4 alone, even for 6 months, failed to induce tu-
mors in our experiment (data not shown), suggesting
that the CCl4 treatment could not induce tumor, but
promoted the hepatocarcinogenesis induced by cMyc
plus shp53. The simplicity and efficiency in inducing
HCC, as well as the resemblance to human hepatocarci-
nogenesis, suggests the utility of this model system in
preclinical studies of HCC [12].
Our data showed that CCl4 induced background liver
fibrosis and significantly enhanced hepatocarcinogenesis
initiated by cMyc overexpression and p53 suppression.
However, the molecular mechanism underlying the in-
creased tumorigenesis remains unclear. As a hepatotoxic
chemical inducing chronic liver injury, CCl4 has been
widely used to induce fibrosis in livers. A persistent in-
jury to the liver leads to hepatocyte death, followed by
compensatory regeneration, chronic inflammation, accu-
mulation of extracellular matrix components, and subse-
quent changes in the tissue microenvironment [7, 26, 27].
A regenerative microenvironment promoting cellular pro-
liferation might enhance tumor initiation in cells express-
ing cMyc plus shp53 [28]. Upregulation of inflammatory
cytokines (e.g., IL-6 and TNF-α) in livers with chronic in-
jury is known to support tumor-promoting microenviron-
ments [29, 30]. Finally, the possibility cannot be ruled out
that the treatment caused a genetic alteration directly or
via upregulation of reactive oxygen species [15, 31], fur-
ther enhancing tumor initiation induced by cMyc plus
shp53. Ongoing studies are needed to investigate the
molecular mechanism underlying the increased hepato-
carcinogenesis of fibrotic livers in the model.
Several genetically engineered mouse (GEM) models for
HCC have been developed, with alterations in candidate
oncogenes or tumor suppressor genes, and significantly
contributed to a better understanding of the genetic
mechanisms underlying hepatocarcinogenesis [10, 11].
Circumventing procedures requiring excessive time and
resources in developing a GEM model, a new method-
ology has been developed for simple generation of a trans-
genic HCC model, employing HT coupled with the SB
transposon system [13, 14]. Many transgenic HCC models
have been developed via HT and successfully applied to
liver cancer research. The common problem with both
traditional genetic models and HT models for HCC is that
they do not consider background liver fibrosis. Consider-
ing that human HCC develops mostly in a fibrotic or cir-
rhotic liver, the lack of fibrosis in the background liver
could be a critical limitation in the HCC models. Applying
the chronic liver injury model, induced by CCl4 treatment,
to a transgenic HCC model developed by HT, a transgenic
HCC model with background liver fibrosis was efficiently
developed within a few months. Considering the simplicity
and efficiency, as well as the resemblance to human HCC,
the model can be effectively applied to preclinical testing
of HCC anticancer therapy and studies of hepatocarcino-
genesis in fibrotic livers.
Conclusions
A transgenic mouse model of hepatocellular carcinoma
(HCC) with background liver fibrosis was developed, com-
bining a chronic liver injury model with liver transgenesis
via hydrodynamics-based transfection. Liver fibrosis sig-
nificantly accelerated hepatocarcinogenesis induced by
cMyc overexpression and p53 suppression.
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post hydrodynamic transfection with transposons encoding cMyc
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Survival graphs. (PDF 209 kb)
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α-SMA: α-smooth muscle actin; CCl4: carbon tetrachloride; CT: CCl4-treated
mouse; GEM: genetically engineered mouse; GFP: green fluorescent protein;
HCC: hepatocellular carcinoma; H&E: hematoxylin & eosin, HSC, hepatic stellate
cell; HT: hydrodynamic transfection; IHC: immunohistochemistry; MP: cMyc plus
shp53; MPC: cMyc plus shp53 with CCl4 treatment; PHI: post hydrodynamic
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Table 1 Summary of tumor incidence in cMyc + shp53 mice treated with vehicle (MP) vs. cMyc + shp53 mice treated with CCl4
(MPC) from the survival study. Livers were harvested from MPC mice following death and from MP mice at the end of the experiment
Total # of micea % of mice with
liver tumors
Average # of tumors
per mouse
Total # of miceb % of mice with
liver tumors
Average # of tumors
per mouse
MP 21 38 % (8/21)* 0.6† 21 38 % (8/21)‡ 0.6§
MPC 31 77 % (24/31)* 9† 24 100 % (24/24)‡ 11.7§
aEntire cohort
bMice that died initially due to CCl4-induced toxicity were excluded (i.e., those died before 50 days post hydrodynamic transfection)
*P < 0.01, Fisher’s exact test. †P < 0.0001, Student’s t-test
‡P < 0.0001, Fisher’s exact test. §P < 0.0001, Student’s t-test
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